The American Journal of Medicine
Volume 123, Issue 7 , Pages 638-645.e4 , July 2010

Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review

Poster was presented at the American College of Cardiology Annual Meeting 2009 in Orlando, Florida on March 29, 2009.

  • Isla M. Ogilvie, PhD

      Affiliations

    • BioMedCom Consultants Inc., Montréal, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Isla Ogilvie, PhD, BioMedCom Consultants Inc., 1405 TransCanada, Suite 310, Montréal, QC H9P2V9, Canada
    • ,
  • Nick Newton, PhD

      Affiliations

    • BioMedCom Consultants Inc., Montréal, Canada
    • ,
  • Sharon A. Welner, PhD

      Affiliations

    • BioMedCom Consultants Inc., Montréal, Canada
    • ,
  • Warren Cowell, MSc

      Affiliations

    • Global Health Economics and Reimbursement, Bayer HealthCare, Uxbridge, England
    • ,
  • Gregory Y.H. Lip, MD

      Affiliations

    • Haemostasis Thrombosis & Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

  • Image Result

    Literature search and study inclusion for oral anticoagulation treatment levels. CHADS2=congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic

    Literature search and study inclusion for oral anticoagulation treatment levels. CHADS2=congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack.

  • Image Result
    Patients with atrial fibrillation and prior stroke/transient ischemic attack: oral anticoagulation treatment levels as a proportion of patients eligible for oral anticoagulation therapy.*Contraindicat

    Patients with atrial fibrillation and prior stroke/transient ischemic attack: oral anticoagulation treatment levels as a proportion of patients eligible for oral anticoagulation therapy.

    *Contraindications taken into account.

  • Image Result
    Patients with atrial fibrillation at high risk of stroke (CHADS2 score): oral anticoagulant treatment levels as a proportion of patients eligible for therapy.*Includes patients treated with both oral

    Patients with atrial fibrillation at high risk of stroke (CHADS2 score): oral anticoagulant treatment levels as a proportion of patients eligible for therapy.

    *Includes patients treated with both oral anticoagulation therapy and antiplatelet therapy.

    †Patients defined as having a CHADS2 score of >1 and a bleeding score of <2 (the n value for this population was not available).

    CHADS2=congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack.

 Funding: This study was funded by Bayer Healthcare, UK.

 Conflict of Interest: Dr. Gregory Y.H. Lip has acted as a consultant for Bayer Healthcare, AstraZeneca, Astellas, and Boehringer; and Warren Cowell is employed by Bayer Healthcare, UK. The other authors have no conflict of interest.

 Authorship: All authors had full access to data for this study and participated in writing and review of the manuscript.

PII: S0002-9343(10)00254-8

doi: 10.1016/j.amjmed.2009.11.025

The American Journal of Medicine
Volume 123, Issue 7 , Pages 638-645.e4 , July 2010

Article Tools

* Image Usage & Resolution